Lipoxygenase Inhibitors

"Lipoxygenase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES.

Descriptor ID	D016859
MeSH Number(s)	D27.505.519.389.480
Concept/Terms	Lipoxygenase Inhibitors Lipoxygenase Inhibitors Inhibitors, Lipoxygenase Arachidonate 15-Lipoxygenase Inhibitors Arachidonate 15-Lipoxygenase Inhibitors 15-Lipoxygenase Inhibitors, Arachidonate Arachidonate 15 Lipoxygenase Inhibitors Inhibitors, Arachidonate 15-Lipoxygenase 15-Lipoxygenase Inhibitors 15 Lipoxygenase Inhibitors Inhibitors, 15-Lipoxygenase Arachidonate 5-Lipoxygenase Inhibitors Arachidonate 5-Lipoxygenase Inhibitors 5-Lipoxygenase Inhibitors, Arachidonate Arachidonate 5 Lipoxygenase Inhibitors Inhibitors, Arachidonate 5-Lipoxygenase 5-Lipoxygenase Inhibitors 5 Lipoxygenase Inhibitors Inhibitors, 5-Lipoxygenase Arachidonate 12-Lipoxygenase Inhibitors Arachidonate 12-Lipoxygenase Inhibitors 12-Lipoxygenase Inhibitors, Arachidonate Arachidonate 12 Lipoxygenase Inhibitors Inhibitors, Arachidonate 12-Lipoxygenase 12-Lipoxygenase Inhibitors 12 Lipoxygenase Inhibitors Inhibitors, 12-Lipoxygenase

Below are MeSH descriptors whose meaning is more general than "Lipoxygenase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Lipoxygenase Inhibitors [D27.505.519.389.480]

Below are MeSH descriptors whose meaning is related to "Lipoxygenase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Lipoxygenase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lipoxygenase Inhibitors" by people in this website by year, and whether "Lipoxygenase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 16 publications over 10 distinct years, with a maximum of 5 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	1	1
1994	1	0	1
1999	1	0	1
2000	1	0	1
2003	1	0	1
2005	2	3	5
2006	0	1	1
2007	1	2	3
2011	1	0	1
2013	1	0	1

Below are the most recent publications written about "Lipoxygenase Inhibitors" by people in Profiles.

Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJ. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013 Jul; 6(7):646-55.

View in: PubMed
Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Harnden SM, Kim V, Marchetti N, Martinez FJ, McEvoy CE, Niewoehner DE, Reilly JJ, Rice K, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Lazarus SC. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD. 2011 Feb; 8(1):21-9.

View in: PubMed
Ji X, Nishihashi T, Trandafir CC, Wang A, Shimizu Y, Kurahashi K. Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur J Pharmacol. 2007 Dec 22; 577(1-3):109-14.

View in: PubMed
Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA. Zyflamend-mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb protein phosphorylation. Cancer Biol Ther. 2007 Feb; 6(2):228-36.

View in: PubMed
Schroeder CP, Yang P, Newman RA, Lotan R. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. J Exp Ther Oncol. 2007; 6(3):183-92.

View in: PubMed
Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene. 2006 Sep 28; 25(44):6015-25.

View in: PubMed
Trandafir CC, Nishihashi T, Ji X, Wang A, Kurahashi K. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery. Clin Exp Pharmacol Physiol. 2005 Dec; 32(12):1027-33.

View in: PubMed
Wang A, Nishihashi T, Trandafir CC, Murakami S, Ji X, Shimizu Y, Kurahashi K. Involvement of endothelial cyclo-oxygenase metabolites in noradrenaline-induced contraction of rat coronary artery. Clin Exp Pharmacol Physiol. 2005 Aug; 32(8):628-32.

View in: PubMed
Devaraj S, Jialal I. Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic Biol Med. 2005 May 01; 38(9):1212-20.

View in: PubMed
Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, Ajani JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. Carcinogenesis. 2005 Apr; 26(4):785-91.

View in: PubMed

People

Explore

Similar Concepts

Top Journals